Journal of Cutaneous and Aesthetic Surgery

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 15  |  Issue : 2  |  Page : 118--123

Management of pre-malignant and malignant non-melanoma skin cancers: A study from a Tertiary Care Hospital of North India


Yasmeen Jabeen Bhat1, Sumaya Zeerak1, Farhan Rasool2, Saniya Akhtar3, Iffat Hassan Shah1, Atiya Yaseen3,  
1 Department of Dermatology, Sexually Transmitted Diseases and Leprosy, Government Medical College, Srinagar, Jammu & Kashmir, India
2 NMC Royal Hospital, Khalifa City A, Abu Dhabi, United Arab Emirates
3 Department of Health, Jammu & Kashmir, India

Correspondence Address:
Sumaya Zeerak
Department of Dermatology, Sexually Transmitted Diseases and Leprosy, Government Medical College, Srinagar 190010, Jammu & Kashmir
India

Abstract

Introduction: The incidence of non-melanoma skin cancers (NMSCs) is increasing over the last few decades. This necessitates an early diagnosis which is nowadays aided by dermoscopy. Once diagnosed early, the treatment armamentarium is diverse and includes both topical and surgical modalities. Objective: Our aim was to diagnose pre-malignant and malignant NMSCs at an early stage and treat them as per the standard protocol. Materials and Materials: Out of 136 patients of pre-malignant and malignant tumors enrolled, 100 were taken up for treatment. These were then classified into various subtypes on the basis of clinical examination and dermoscopy. The selected patients were subjected to topical treatment or surgical modalities, wide local excision or flap excision, based on the type of tumor and its size. Results: The pre-malignant group included actinic keratoses, Bowen’s disease, and keratoacanthoma, whereas the malignant group included undifferentiated squamous cell carcinoma (SCC), differentiated SCC, pigmented basal cell carcinoma (BCC), nodulo-ulcerative BCC, and superficial BCC. Actinic keratoses, superficial BCCs, and five cases of keratoacanthoma were treated with topical therapies with a resolution of 90% in 86.8% cases. All the remaining cases (62 in number) were treated with conventional and flap surgery with 88% and 89.1% clearance rates, respectively, with complications in only 7 patients. Conclusion: A prompt identification of NMSCs can enable selection of the appropriate treatment modality for a specific lesion and thus reduce their associated morbidity and mortality.



How to cite this article:
Bhat YJ, Zeerak S, Rasool F, Akhtar S, Shah IH, Yaseen A. Management of pre-malignant and malignant non-melanoma skin cancers: A study from a Tertiary Care Hospital of North India.J Cutan Aesthet Surg 2022;15:118-123


How to cite this URL:
Bhat YJ, Zeerak S, Rasool F, Akhtar S, Shah IH, Yaseen A. Management of pre-malignant and malignant non-melanoma skin cancers: A study from a Tertiary Care Hospital of North India. J Cutan Aesthet Surg [serial online] 2022 [cited 2022 Aug 9 ];15:118-123
Available from: https://www.jcasonline.com/text.asp?2022/15/2/118/351503


Full Text



 Introduction



Malignancies are on the rise globally and skin cancers are no exception. The incidence of cutaneous malignancies has been increasing over the last few decades.[1] India too is witnessing a sharp upsurge in their incidence. Non-melanoma skin cancers (NMSCs) form one of the two major groups of cutaneous malignancies and the other being cutaneous melanoma. Excluding mucosal tumors, NMSCs broadly include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).[2]

The precursor lesions of NMSCs include actinic keratoses, Bowen’s disease, and keratoacanthoma in addition to some uncommon variants.[3] All three have a considerable malignant potential, with a tendency to transform into invasive SCC.[4] If treated early, the risk is negated, resulting in considerable reduction in morbidity and mortality.

However, the diagnosis becomes challenging at times and can be eased by performing dermoscopy. The latter has emerged as a novel tool in recent years in the identification of various pre-malignant and malignant cutaneous tumors. Each one of these lesions has a characteristic dermoscopic appearance enabling easy screening and thus early treatment.

The treatment options are multiple for both the groups. Topical therapy is reserved for smaller, superficial, low-risk tumors.[5] Surgery is the mainstay of treatment for all types of NMSCs. It includes Mohs micrographic surgery which is the best modality for larger tumors (> 2 cm), for invasive histologic subtypes, and for tumors at locations with higher risk of recurrence. Conventional/standard surgical excision is preferred for well-defined, smaller, nodular pre-malignant, and malignant tumors.[6] In large lesions and those at lax sites, reconstruction with local or distant flaps also constitutes an important surgical option.[7]

Owing to the increasing incidence of these tumors in our valley in the last few years and the emerging role of dermoscopy in their diagnosis, we undertook this study on the screening and treatment of various NMSCs.

 Materials and Methods



This was a prospective hospital-based study conducted on patients attending the outpatient department of a tertiary care hospital, for a period of 2 years from August 2017 to July 2019. During this period, 136 patients presenting with clinical features of pre-malignant or malignant non-melanoma skin tumors were taken up for the study.

All the patients were subjected to a detailed history, general physical, and systemic examination. This was followed by a detailed cutaneous examination to ascertain the clinical variant. Dermoscopy was then done in all the cases to confirm the diagnosis, differentiate pre-malignant from malignant tumors in doubtful cases, and ease their sub-categorization. Histopathology of the biopsied specimen was additionally done (punch, edge, or elliptical or of the entire specimen after excision) to validate the diagnosis. Relevant investigations (hemogram, bleeding and clotting time, blood sugar) were done in patients who needed surgical intervention.

After proper stratification, the following treatment modalities were employed:

1. Topical treatment: imiquimod 5% or 5-fluorouracil for actinic keratoses and superficial BCCs;

2. Intralesional injection of methotrexate for keratoacanthomas (in those cases with co-morbidities or those reluctant for surgery);

3. Surgical intervention:a) Simple/conventional excision: wide local excision for BCCs (as most of them were low risk) and remaining cases of keratoacanthoma;

b) Flap excision for Bowen’s disease and SCCs.

In both types of excision, the extent of margins excised was done in accordance with the guidelines of the European Dermatology Forum and British Association of Dermatology. They, respectively, recommend 3–4 or 4–5 mm peripheral margins for low-risk BCCs (<2 cm in diameter) and 5–10 mm or greater than 5 mm peripheral margins for high-risk BCCs.[8]

In flap excision, the area to be excised was marked in a rhomboidal fashion with each side equal and the angles marked as 60° and 120°. A V-shaped flap was marked starting from a point adjacent to the angle of 120°, with both limbs of the flap also being equal and forming an angle of 60°. The lesion was then excised and the flap was undermined in the subcutaneous plane. This was followed by transposition of the flap over the rhomboidal defect in such a manner that the “V” of the flap was approximated with the diagonally opposite side to create least tension, in accordance with the conventional Limberg’s flap.[9] Closure was done in the deeper layers and then in the skin using vicryl and prolene, respectively. The wound was properly dressed and a drain was placed in some selected patients.

In non-operated patients, response to treatment was assessed at biweekly intervals for a period of 3 months or till the lesions resolved and then at 3-monthly intervals for a period of 1 year.

In operated cases, the patients were followed for any post-operative complications till the wound healed and then at 3-monthly intervals for 1 year.

 Results



Of the 136 cases, 36 tumors were not amenable to standard dermatological treatment (either due to large size or atypical location—nasolabial fold, medial or lateral canthi, etc.) and were thus referred to plastic surgery department for further management. The remaining 100 cases were enrolled in our study.

A total of 100 cases of pre-malignant and malignant tumors were enrolled. The age of the patients ranged from 45 to 80 years with a mean age of 58.6 years. Males outnumbered females accounting for 68 (68%) cases, whereas the latter were just 32 (32%) in number with a male: female ratio of 2.1:1.

After proper clinical examination and dermoscopy, the tumors were classified into two broad groups: pre-malignant and malignant. The pre-malignant group accounted for 63% of the cases and included actinic keratoses (29%), Bowen’s disease (19%) [Figure 1]A-C and [Figure 2]A, and keratoacanthoma (15%) [Figure 3]A. The remaining 37% cases were malignant in nature and included undifferentiated SCCs (10%), differentiated SCCs (8%) [Figure 4]A-C, pigmented BCCs (8%), nodulo-ulcerative BCCs (7%), and superficial BCCs (4%). Taken together, actinic keratosis was the most common lesion (29%), followed by Bowen’s disease (19%), BCCs (19%), SCCs (18%), and keratoacanthoma (15%) [Table 1].{Figure 1} {Figure 2} {Figure 3} {Figure 4} {Table 1}

Face was the most common site (42 cases), followed by the thigh and leg (31 cases), hand and forearm (15 cases), abdomen (7 cases), back (3 cases), and neck (2 cases).

The dermoscopic features seen in these various tumors are summarized in [Table 2] [Figure 2]B, [Figure 3]B, [Figure 3]C, [Figure 5]A, and [Figure 6]B.{Table 2} {Figure 5} {Figure 6}

Out of these, actinic keratoses and superficial BCCs were treated with topical therapies (either with imiquimod 5% or 5-fluorouracil 1% cream along with frequent sunscreen application) [Figure 7]A and [B]. Half of the patients received imiquimod and half received 5-FU. Imiquimod 5% was applied on alternate days and then washed after 8–10 h. 5-Fluorouracil 1% cream was also given in the same manner. Both were given for a period of 3 months or till clinical resolution (>90% reduction in size) was achieved, which ever was earlier. Selection of patients for these topical modalities was done on an alternate basis (i.e., imiquimod to one patient and 5-FU to the second and so on).{Figure 7}

Five cases of keratoacanthoma were subjected to intralesional methotrexate (I/L MTX), 15 mg/mL, administered as 2–3 weekly injections of 1 mL each for a total of three doses [Table 1] and [Figure 3D]. Thus 38 cases were treated by non-surgical modalities.

Pigmented BCCs (8 cases), nodulo-ulcerative BCCs (7 cases), and operable keratoacanthomas (10 in number) were subjected to conventional excision, making a total of 25 cases. Larger lesions such as Bowen’s disease (all being >3 cm) which were 19 in number and all SCCs (18 cases) were subjected to rhomboidal flap surgery (37 in total).

In the 38 non-operated cases, 33 (86.8%) resolved by 90% at the end of 1 year. The remaining non-operated cases resolved partially and were subjected to regular follow-up after 1 year also. The unresolved cases were subjected to alternative treatment options. A few side effects such as intense erythema, bulla formation, crusting, and hypopigmentation were seen in eight patients in the first few weeks of treatment [Table 3].{Table 3}

In the 62 operated patients (conventional and flap), the results were very good. Fifty-five patients (22 from the conventional excision group and 33 from the flap surgery group) showed complete clearance with no immediate or delayed post-operative complications and no relapse at the end of 1 year [Figures 2C], [5B], and [6C]. However, in seven patients, complications were seen. These included localized soft-tissue infection in three cases (resolved with antibiotics) and one case each of dehiscence (resutured), delayed healing, retention of suture material, and incomplete excision (diagnosed after histopathology and re-excised) [Table 3].

 Discussion



NMSCs are not usually life-threatening but can lead to significant morbidity due to local extension. Some of them like SCCs show greater propensity for metastasis, thus resulting in considerable morbidity and mortality.[10] Hence, prompt identification of the tumor followed by proper staging and treatment is highly important for favorable outcome. This necessitates a proper local and systemic examination followed by a dermoscopic examination of the lesion (to confirm the type of the tumor), before proceeding to its definitive management.

In our study, the mean age of the patients was 58.6 years which was comparable to other studies. In a study on skin cancers from Punjab, the mean age of the patients was 62 years.[11] This is in accordance with a late onset of NMSCs seen in majority of the patients worldwide. The gender distribution of our cases (M: F ratio of 2.1:1) was comparable to a study from North India wherein the ratio was 1.8:1.[12]

The pre-malignant tumors (63%) were more common than the malignant tumors (37%) and among the pre-malignant ones, actinic keratosis was the commonest. Similar results were obtained in a study by Sajad et al.[13]

Topical therapy and I/L MTX yielded substantial results (90% resolution in 86.8% cases) in the cases enrolled. Between the two topicals, imiquimod gave better results with less cutaneous side effects. Our results were similar to studies wherein substantial resolution was noted in the patients, following topical imiquimod application.[14] Comparable results were observed by Annest et al.,[15] who found a 92% resolution rate with I/L MTX. This could be due to suitable patient selection (pre-malignant lesions and superficial BCCs) in our study and the reference study.

Wide local excision is one of the preferred modalities for smaller NMSCs, especially at centers in which Mohs surgery is not feasible. The overall recurrence rate is estimated at <2% at 5 years following complete excision in multiple studies.[16],[17] In a study by Bisson et al.,[18] complete clearance was achieved in 93% of the cases. In our study, we obtained a comparable clearance rate of 88% following wide local excision with no relapse at 1 year. In three patients, incomplete excision was demonstrated after histopathology of the excised tumor. Such patients were subjected to re-excision.

Local flap surgery is the standard surgical modality for large lesions in which simple closure is not possible. Moreover, it provides a cosmetic effect as the donor tissue provides a similar color, texture, and thickness to the recipient area (being adjacent to it) and has higher survival rate when compared with a skin graft.[19]

Among the multiple variants of flaps, we preferred the rhomboidal flap (a subtype of Limberg’s flap), being well suited for large defects on the trunk and limbs. Numerous studies have demonstrated the safety and versatility of this flap in many areas of the body.[20] In a study by Divya et al.,[21] 8 out of 12 cases (66.7%) operated by the rhomboidal flap method showed excellent results. Our study too yielded substantial results wherein 89.1% of the cases were operated successfully with no complications or sequelae.

 Conclusion



So non-melanoma skin tumors should be promptly identified and subtyped by clinical examination, dermoscopy, and histopathology (depending on the case). This will help the clinician to delineate the treatment modality (medical or surgical) specific to each case and eventually reduce the long-term morbidity and mortality due to these tumors. Inability to perform skin grafts and other types of flap surgeries were the limitations of this surgery.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Demers AA, Nugent Z, Mihalcioiu C, Wiseman MC, Kliewer EV Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol 2005;53:320-8.
2Preston DS, Stern RS Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649-62.
3Pinkus H, Mehregan AH Premalignant skin lesions. Clin Plast Surg 1980;7:289-300.
4Dodds A, Chia A, Shumack S Actinic keratosis: Rationale and management. Dermatol Ther (Heidelb) 2014;4:11-31.
5Love WE, Bernhard JD, Bordeaux JS Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: A systematic review. Arch Dermatol 2009;145:1431-8.
6Thissen MR, Neumann MH, Schouten LJ A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135:1177-83.
7Rao JK, Shende KS Overview of local flaps of the face for reconstruction of cutaneous malignancies: Single institutional experience of seventy cases. J Cutan Aesthet Surg 2016;9:220-5.
8Nahhas AF, Scarbrough CA, Trotter S A review of the global guidelines on surgical margins for nonmelanoma skin cancers. J Clin Aesthet Dermatol 2017;10:37-46.
9Mathew J, Varghese S, Jagadeesh S The Limberg flap for cutaneous defects—A two year experience. Indian J Surg 2007;69:184-6.
10Kansara S, Bell D, Weber R Surgical management of non melanoma skin cancer of the head and neck. Oral Oncol 2020;100:104485.
11Lal ST, Banipal RP, Bhatti DJ, Yadav HP Changing trends of skin cancer: A tertiary care hospital study in Malwa region of Punjab. J Clin Diagn Res 2016;10:PC12-5.
12Deo SV, Hazarika S, Shukla NK, Kumar S, Kar M, Samaiya A Surgical management of skin cancers: Experience from a regional cancer centre in North India. Indian J Cancer 2005;42:145-50.
13Sajad P, Hassan I, Reshi R, Khan A, Qureshi W Pattern of skin tumours in Kashmir Valley of North India: A hospital based clinicopathological study. Int J Inf Res Rev 2015;2:376-81.
14Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50:722-33.
15Annest NM, VanBeek MJ, Arpey CJ, Whitaker DC Intralesional methotrexate treatment for keratoacanthoma tumors: A retrospective study and review of the literature. J Am Acad Dermatol 2007;56:989-93.
16Walker P, Hill D Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol 2006;47:1-12.
17Griffiths RW, Suvarna SK, Stone J Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg 2005;58:795-805.
18Bisson MA, Dunkin CS, Suvarna SK, Griffiths RW Do plastic surgeons resect basal cell carcinomas too widely? A prospective study comparing surgical and histological margins. Br J Plast Surg 2002;55:293-7.
19Kwon KH, Lee DG, Koo SH, Jo MS, Shin H, Seul JH Usefulness of v-y advancement flap for defects after skin tumor excision. Arch Plast Surg 2012;39:619-25.
20Turan T, Kuran I, Ozcan H, Baş L Geometric limit of multiple local Limberg flaps: A flap design. Plast Reconstr Surg 1999;104:1675-8.
21Divya GK, Shilpa K, Sarvajnamurthy S, Loganathan E, Vasudevan B, Chitrika GB, et al. Outcome of flap surgeries in dermatosurgical unit at a tertiary care centre in India with a review of literature. J Cutan Aesthet Surg 2016;9:226-31.